EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
Lung cancer in never smokers: The role of different risk factors other than tobacco smoking
L Corrales, R Rosell, AF Cardona, C Martin… - Critical reviews in …, 2020 - Elsevier
Lung cancer (LC), the leading cause of cancer-related deaths worldwide, is a complex and
highly heterogeneous disease. Additional to its biological complexity, LC patients are often …
highly heterogeneous disease. Additional to its biological complexity, LC patients are often …
Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung …
PC Hsu, DM Jablons, CT Yang, L You - International journal of molecular …, 2019 - mdpi.com
The epidermal growth factor receptor (EGFR) pathway is a well-studied oncogenic pathway
in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC patients (15 …
in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC patients (15 …
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
J Hou, H Li, S Ma, Z He, S Yang, L Hao, H Zhou… - Biomarker …, 2022 - Springer
Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
Objectives The burden of epidermal growth factor receptor (EGFR) exon 20 insertion
mutation (Exon 20ins) in non-small cell lung cancer is not well understood. A systematic …
mutation (Exon 20ins) in non-small cell lung cancer is not well understood. A systematic …
[HTML][HTML] Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo-and gene therapy
OB Garbuzenko, A Kuzmov, O Taratula, SR Pine… - Theranostics, 2019 - ncbi.nlm.nih.gov
Abstract Non-Small Cell Lung Carcinoma (NSCLC), is the most common type of lung cancer
(more than 80% of all cases). Small molecule Tyrosine Kinase (TK) Inhibitors acting on the …
(more than 80% of all cases). Small molecule Tyrosine Kinase (TK) Inhibitors acting on the …